Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

doi:10.1158/1535-7163.MCT-17-0456

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Molecular cancer therapeutics - 1 Nov 2017

Germann Ursula A, Furey Brinley F, Markland William, Hoover Russell R, Aronov Alex M, Roix Jeffrey J, Hale Michael, Boucher Diane M, Sorrell David A, Martinez-Botella Gabriel, Fitzgibbon Matthew, Shapiro Paul, Wick Michael J, Samadani Ramin, Meshaw Kathryn, Groover Anna, DeCrescenzo Gary, Namchuk Mark, Emery Caroline M, Saha Saurabh, Welsch Dean J

Abstract excerpt

Aberrant activation of signaling through the RAS-RAF-MEK-ERK (MAPK) pathway is implicated in numerous cancers, making it an attractive therapeutic target. Although BRAF and MEK-targeted combination therapy has demonstrated significant benefit beyond single-agent options, the majority of patients develop resistance and disease progression after approximately 12 months. Reactivation of ERK signaling is a common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyrroles

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 28939558
DOI: 10.1158/1535-7163.MCT-17-0456

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).PMID 28939558Read ↗

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Design and biological characterization of a series of dual mechanism ERK1/2 inhibitors with a Triazolopyridinone core.Semantic proximity Read ↗

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.Semantic proximity Read ↗

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.Semantic proximity Read ↗

Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.Semantic proximity Read ↗

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.Semantic proximity Read ↗

Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.